Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development.

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in ...

The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...

Roche’s injectable component C5 inhibitor has been recommended by the National Institute for Health and Care Excellence (NICE) to treat the rare blood disorder paroxysmal nocturnal haemoglobinuria ...

It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...

You can now start working on your entries and don’t forget to get them to us by Thursday 14 November by midnight to qualify for our early bird pricing. Entry deadline is Thursday 21 November and a ...

GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...

Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...

Researchers from the Institute of Cancer Research (ICR) have highlighted the potential benefits of treating bladder cancer with personalised radiotherapy. More than 130,000 patients are treated on the ...

Bristol Myers Squibb (BMS) has announced positive results from a phase 3b/4 study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in moderate-to-severe scalp psoriasis. Data from the ongoing ...